Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-Ascending Dose Safety, Tolerability, and Pharmacokinetic Study of AG-236 Administered as a Subcutaneous Dose in Healthy Male and Female Participants

NCT07075640 is registered in ClinicalTrials.gov with Agios Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07075640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07075640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-Ascending Dose Safety, Tolerability, and Pharmacokinetic Study of AG-236 Administered as a Subcutaneous Dose in Healthy Male and Female Participants
Lead sponsor
Agios Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 7, 2025
Completion date
August 31, 2026
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants